This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): atorvastatin calcium, Zarator (Spain), Cardyl (Spain)
Description: The active ingredient of Lipitor, Atorvastin calcium, inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol. Lipitor has been shown to reduce total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B) in patients.
Deal Structure: Astellas and Pfizer co-promote Lipitor in Japan.
In March 2012, Pfizer and Astellas announced that the companies have agreed to continue and expand their partnership built through Lipitor (atorvastatin calcium hydrate) by partly revising a Development and Marketing Agreement for Lipitor (the DMA). Pursuant to this agreement, the term of the DMA has been extended from July 2016 to March 2021. Additionally, certain financial terms of the DMA, including co-promotion fee rate from December 2011 to November 2013, have been revised.
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: